Tag Archives: Memorial Sloan Kettering Cancer Center

July, 2018

20 July
SELLAS Receives Fast Track Designation from FDA for Galinpepimut-S for the Treatment of Multiple Myeloma

NEW YORK, July 20, 2018 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast …
Share

13 December
Daiichi Sankyo and Puma Collaborate with Major Cancer Center in HER2-Mutated Cancer

TOKYO, BASKING RIDGE, N.J. & LOS ANGELES–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Puma Biotechnology, Inc. (Nasdaq: PBYI) have announced a preclinical research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to explore the combination of Daiichi Sankyo’s investigational antibody drug conjugate DS-8201 and Puma Biotechnology’s irreversible pan-HER …
Share

1 June
Philips and MSK Enter Partnership on Genome Analytics for Prostate Cancer Precision Medicine

AMSTERDAM and NEW YORK, June 1, 2017 /PRNewswire/ — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Memorial Sloan Kettering Cancer Center (MSK), the world’s oldest and largest private cancer center, today announced a research collaboration to help improve the understanding of pancreatic cancer and …
Share

5 August
Juno Partners with Memorial Sloan Kettering and Eureka Therapeutics for CAR T Cell Therapy in Multiple Myeloma

SEATTLE & NEW YORK & EMERYVILLE, Calif.–(BUSINESS WIRE)–Aug. 4, 2016– Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, announced today that it has entered into an exclusive license agreement with Memorial Sloan Kettering Cancer Center(MSK) and Eureka …
Share

2 March
FDA Grants Breakthrough Therapy Status to Atara and MSK’s T Cell Therapy

Atara Biotherapeutics, Inc. and partner Memorial Sloan Kettering Cancer Center (MSK) announced that they have received Breakthrough Therapy designation for its promising T cell therapy. The companies said that the US Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Atara’s optioned cytotoxic T lymphocytes activated against Epstein-Barr Virus …
Share